Please login to the form below

Not currently logged in
Email:
Password:

Chugai gains FDA breakthrough status for rare CNS treatment

Adds to company's BTD roll-call

fda

The FDA has granted Breakthrough Therapy Designation to Chugai’s satralizumab, a treatment currently in phase 3 for the rare CNS disorders neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NMOSD).

Chugai is part of the Roche group, and the announcement marks the seventh Breakthrough Designation Therapy (BTD) received for four drugs discovered by the Japanese firm, which include haemophilia treatment Hemlibra.

Satralizumab is a recycling antibody created via Chugai’s proprietary antibody engineering technologies, and works by blocking the autoimmune condition underlying NMO/NMOSD.

"We are delighted by the FDA’s designation for this innovative antibody based on the results of a Chugai-initiated global phase 3 study” said Chugai’s executive vice president, co-head of project & lifecycle management unit, Dr. Yasushi Ito.

“Satralizumab is designed to inhibit signalling of the inflammatory cytokine IL-6, which is known to play a role in the pathogenesis of NMO/NMOSD. We continue our efforts to hopefully bring satralizumab as a new treatment option as soon as possible to people living with this devastating disease with no approved drugs.”

The BTD designation for satralizumab is based on data from the phase 3 study (SAkuraSky study, NCT02028884) evaluating it in addition to baseline therapy.

NMOSD is a rare, lifelong, and debilitating autoimmune disease of the central nervous system (CNS) characterised by inflammatory lesions in the optic nerves and spinal cord. Patients with NMOSD frequently experience a relapsing disease course with repeated attacks leading to accumulating neurological damage and disability, often including visual impairment, motor disability, and loss of quality of life. In some cases, attacks of NMOSD result in death.

Just yesterday the company announced results from a further phase 3 trial of the drug as a monotherapy in the disease. The therapy achieved its primary endpoint, a significant reduction in the risk of relapse was confirmed in patients who received satralizumab compared to a placebo arm.

Dr. Yasushi Ito confirmed that the company would now work to prepare the drug for filing with regulators.

Article by
Andrew McConaghie

20th December 2018

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics